
MAY 2 3 2003



#### **CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurelee A. Duncan

Type or print name

Damelle & Dancon

May 21/2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 2 8 2003

TECH CENTER 1600/2900

IN RE APPLICATION OF

IWANOWICZ ET AL.

APPLICATION NO: 09/840,503 🗸

FILED: APRIL 23, 2001

FOR: HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference(s) cited on the attached form(s) PTO-1449.

Copy of this references is enclosed herewith.

05/28/2003 AWDHDAF1 00000044 193880 09840503

01 FC:1806

180.00 CH

The Examiner is requested to consider the foregoing information in relation to this application and indicate that the reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Laurelee A. Duncan Attorney for Applicants

Reg. No. 44,096

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-5323

Date: May 21, 2003.

- 2 -

CASE QA231 J

#### **CERTIFICATE OF MAILING**

Thereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurelee A. Duncan

Type or print name

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

IWANOWICZ ET AL.

**APPLICATION NO: 09/840,503** 

FILED: APRIL 23, 2001

FOR: HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME

TECH CENTER 1600/2900

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-5323

Date: 1/2003

Laurelee A. Duncan Attorney for Applicants

Reg. No. 44,096